Lilly's Cyramza gets first EU CHMP nod
This article was originally published in Scrip
Lilly's novel targeted anticancer Cyramza (ramucirumab) is set for EU approval in its first indications, in stomach cancer, following a positive opinion from the CHMP at its latest meeting.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.